Cellebrite DI Ltd. Reports 20% Revenue Growth and 34% Increase in Adjusted EBITDA for Q1 2025

Reuters
05-14
<a href="https://laohu8.com/S/CLBT">Cellebrite</a> DI Ltd. Reports 20% Revenue Growth and 34% Increase in Adjusted EBITDA for Q1 2025

Cellebrite DI Ltd. reported its financial results for the first quarter of 2025, highlighting a revenue increase to $107.5 million, marking a 20% growth primarily driven by a 21% increase in subscription revenue. The company's Annual Recurring Revenue $(ARR)$ grew by 23%, reaching $408.0 million. Adjusted EBITDA for the quarter stood at $23.7 million, reflecting a 34% year-over-year increase, with an adjusted EBITDA margin of 22.0%. In recent business developments, Cellebrite introduced its Spring 2025 Release on May 6, 2025, which features the new Cellebrite Cloud and AI-powered innovations across its product portfolio. These advancements are designed to enhance digital workflows, expedite investigations, and boost operational productivity and efficiency. The company is also advancing its Case-to-Closure Platform into the next-generation Digital Investigation Platform as more customers adopt a broader range of its integrated solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellebrite DI Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450878-en) on May 14, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10